CSIMarket
 


Cellectar Biosciences Inc   (CLRB)
Other Ticker:  
 

Cellectar Biosciences Inc 's Tangible Leverage Ratio

CLRB's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth




CLRB Tangible Leverage Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Tangible Equity Change -66.96 % -54.09 % -45.34 % -39.69 % 137.83 %
Y / Y Total Liabilities Change 109.82 % 61.08 % -7.85 % 11.96 % -24.58 %
Tangible Leverage Ratio MRQ 0.5 0.27 0.17 0.12 0.08
Overall Ranking # # # # #
Seq. Tangible Equity Change -36.86 % -25.78 % -17.66 % -14.36 % -12.27 %
Seq. Total Liabilities Change 16.56 % 21.07 % 17.04 % 27.04 % -10.51 %



Tangible Leverage Ratio third quarter 2022 Comment
Due to net new borrowings of 16.56%, Tangible Leverage Ratio detoriated to 0.5, above company's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry Cellectar Biosciences Inc achieved lowest Tangible Leverage Ratio. While total ranking remained unchanged compare to previous quarter at no. .

Explain Tangible Leverage Ratio?
What is CLRB Market Share?
Tangible Leverage Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Tangible Leverage Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Cellectar Biosciences Inc 's Tangible Equity $ 13 Millions Visit CLRB's Balance sheet
Cellectar Biosciences Inc 's Total Liabilities $ 6 Millions Visit CLRB's Balance sheet
Source of CLRB's Sales Visit CLRB's Sales by Geography


Cumulative Cellectar Biosciences Inc 's Tangible Leverage Ratio

CLRB's Tangible Leverage Ratio for the trailling 12 Months

CLRB Tangible Leverage Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Tangible Equity TTM Growth -66.96 % -54.09 % -45.34 % -39.69 % 137.83 %
Y / Y Total Liabilities TTM Growth 109.82 % 61.08 % -7.85 % 11.96 % -24.58 %
Tangible Leverage Ratio TTM 0.22 0.14 0.1 0.09 0.08
Total Ranking TTM # 219 # 157 # 300 # 176 # 149
Seq. Tangible Equity TTM Growth -36.86 % -25.78 % -17.66 % -14.36 % -12.27 %
Seq. Total Liabilities TTM Growth 16.56 % 21.07 % 17.04 % 27.04 % -10.51 %


TTM Tangible Leverage Ratio Comment
On the trailing twelve months basis Due to net new borrowings of 16.56%, Tangible Leverage Ratio improved to 0.22, above Cellectar Biosciences Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 75 other companies have achieved lower Tangible Leverage Ratio than Cellectar Biosciences Inc . While total ranking remained unchanged compare to previous quarter at no. 219.

Explain Tangible Leverage Ratio?
What is CLRB Market Share?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 76
Healthcare Sector # 130
Within the Market # 219


TTM Tangible Leverage Ratio Statistics
High Average Low
0.31 0.19 0.09
(Mar 31 2020)   (Sep 30 2021)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioSep 30 2022 MRQ Total LiabilitiesSep 30 2022 MRQ Tangible Equity
Trevena inc   1.33 $ 29.156  Millions$ 21.863  Millions
Tempest Therapeutics Inc   1.31 $ 35.024  Millions$ 26.773  Millions
Blueprint Medicines Corporation  1.28 $ 818.085  Millions$ 640.307  Millions
2seventy Bio Inc   1.27 $ 385.564  Millions$ 303.645  Millions
Sellas Life Sciences Group Inc   1.25 $ 13.404  Millions$ 10.683  Millions
Capricor Therapeutics inc   1.25 $ 19.244  Millions$ 15.426  Millions
Unicycive Therapeutics Inc   1.20 $ 5.551  Millions$ 4.626  Millions
Acasti Pharma Inc   1.19 $ 20.677  Millions$ 17.390  Millions
Ardelyx inc   1.16 $ 77.811  Millions$ 66.861  Millions
Arvinas Inc   1.15 $ 713.300  Millions$ 621.500  Millions
Lifevantage Corp  1.14 $ 35.710  Millions$ 31.336  Millions
Marinus Pharmaceuticals Inc   1.14 $ 93.338  Millions$ 82.004  Millions
Sonoma Pharmaceuticals Inc  1.13 $ 7.941  Millions$ 7.021  Millions
Sigilon Therapeutics Inc   1.13 $ 50.208  Millions$ 44.410  Millions
Geron Corp  1.11 $ 120.608  Millions$ 108.172  Millions
Royalty Pharma Plc  1.11 $ 11,520.505  Millions$ 10,416.403  Millions
Selecta Biosciences Inc  1.10 $ 93.358  Millions$ 84.907  Millions
Nektar Therapeutics  1.10 $ 368.783  Millions$ 335.722  Millions
Alaunos Therapeutics Inc   1.10 $ 35.231  Millions$ 32.113  Millions
Durect Corp  1.09 $ 31.285  Millions$ 28.685  Millions
Tg Therapeutics inc   1.07 $ 106.828  Millions$ 99.682  Millions
Oncorus Inc   1.05 $ 84.369  Millions$ 79.996  Millions
Immunogen inc   1.02 $ 180.792  Millions$ 178.007  Millions
Otonomy Inc   1.02 $ 21.719  Millions$ 21.397  Millions
Aptevo Therapeutics Inc   1.01 $ 15.933  Millions$ 15.762  Millions
Arcus Biosciences Inc   0.99 $ 695.121  Millions$ 698.701  Millions
Spero Therapeutics Inc   0.98 $ 31.992  Millions$ 32.484  Millions
F star Therapeutics Inc   0.97 $ 25.953  Millions$ 26.622  Millions
Dynavax Technologies Corporation  0.93 $ 465.634  Millions$ 498.741  Millions
Bioxcel Therapeutics Inc   0.93 $ 117.832  Millions$ 126.986  Millions

Date modified: 2022-11-06T02:10:30+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SHQA's Profile

Stock Price

SHQA's Financials

Business Description

Fundamentals

Charts & Quotes

SHQA's News

Suppliers

SHQA's Competitors

Customers & Markets

Economic Indicators

SHQA's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071